
Novartis has announced that its product ribociclib (LEE011) has been granted fast-track review status as a first-line treatment of advanced …
The FDA has shown Pfizer’s breast cancer drug Ibrance an early green light to treat patients who are at the …

Pfizer’s experimental breast cancer drug palbociclib has successfully extended progression-free survival in a Phase II trial. The pill was administered …

